STOCKHOLM, SWEDEN--(Marketwire - July 16, 2008) - Symphogen A/S and Biovitrum AB (publ) (STO: BVT) today announced the recruitment of the first patient into a Phase II clinical trial, initiated in June, to evaluate the safety and efficacy, and explore the dose range of Sym001 in Idiopathic Thrombocytopenic Purpura (ITP) patients. Sym001 is a recombinant, polyclonal anti-Rhesus D antibody product candidate. Symphogen and Biovitrum are jointly developing Sym001 under a 50/50 co-development and commercialization agreement announced in February 2006.
